AstraZeneca Pharma India Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
AstraZeneca Pharma India heeft een totaal eigen vermogen van ₹7.1B en een totale schuld van ₹45.9M, wat de schuld-eigenvermogensverhouding op 0.6% brengt. De totale activa en totale passiva bedragen respectievelijk ₹10.8B en ₹3.7B. De EBIT AstraZeneca Pharma India is ₹1.4B waardoor de rentedekking -4.5 is. Het heeft contanten en kortetermijnbeleggingen van ₹5.1B.
Belangrijke informatie
0.6%
Verhouding schuld/eigen vermogen
₹45.90m
Schuld
| Rente dekkingsratio | -4.5x |
| Contant | ₹5.06b |
| Aandelen | ₹7.12b |
| Totaal verplichtingen | ₹3.66b |
| Totaal activa | ₹10.78b |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors
Sep 18
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability
Jun 03Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S
May 22We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?
Aug 02Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Jul 12Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹9.3B ) ASTRAZEN } overtreffen de korte termijn passiva ( ₹3.6B ).
Langlopende schulden: De kortetermijnactiva ASTRAZEN ( ₹9.3B ) overtreffen de langetermijnschulden ( ₹89.9M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: ASTRAZEN heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van ASTRAZEN is de afgelopen 5 jaar gestegen van 0% naar 0.6%.
Schuldendekking: De schuld van ASTRAZEN wordt goed gedekt door de operationele kasstroom ( 607.2% ).
Rentedekking: ASTRAZEN verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.